Pipeline Report: January 2022 | Articles

Cosibelimab Elicits Encouraging Responses in Metastatic Cutaneous Squamous Cell Carcinoma

January 25th 2022

The PD-L1 antibody cosibelimab, when given at a fixed dose of 800 mg every 2 weeks, elicited a promising objective response rate with acceptable safety and tolerability in patients with metastatic cutaneous squamous cell carcinoma, meeting the primary end point of a phase 1 registration-enabling trial.

ADXS-503 Plus Pembrolizumab Shows Early Clinical Benefit, Safety in Metastatic NSCLC

January 13th 2022

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.

Alpha DaRT Elicits Complete Responses in Malignant Skin and Soft Tissue Cancers

January 11th 2022

The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.

Devimistat Plus Hydroxychloroquine Shows Early Promise in Relapsed Clear Cell Sarcoma

January 7th 2022

No dose-limiting toxicities have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat and hydroxychloroquine in the dose-escalation portion of the ongoing phase 1/2 APOLLO 613 trial.

CA-4948 Shows Early Activity, Tolerability in Relapsed/Refractory AML and High-Risk MDS

January 7th 2022

CA-4948 monotherapy was found to have preliminary activity with acceptable safety and tolerability in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes, according to updated data from an ongoing phase 1/2 trial.

Pembrolizumab/Pepinemab Combo Safe, Well Tolerated in Advanced, Recurrent, or Metastatic HNSCC

January 7th 2022

The combination of pembrolizumab and pepinemab showcased encouraging safety and tolerability when given as first-line treatment in patients with advanced, recurrent, or metastatic head and neck squamous cell carcinoma.

Mirati and Verastem Combine to Address Unmet Need in KRAS G12C–Mutant NSCLC

January 5th 2022

Mirati Therapeutics and Verastem Oncology have entered a nonexclusive clinical collaboration to evaluate the combination of adagrasib plus VS-6766 for patients with non–small cell lung cancer harboring a KRAS G12C mutation who have progressed on a KRAS G12C inhibitor in a phase 1/2 trial.